Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment

Bibliography

• HORVATH L, BOYER M, CLARKE S et al.: Carboplatin and vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer. Lung Cancer (2001) 32:173-178.
   PubMed Web of Science ®Google Scholar
• CASSIDY J, MISSET JL: Oxaliplatin-related side effects: characteristics and management. Semin. Oncol. (2002) 29(5 Suppl. 15):11-20.
   PubMed Web of Science ®Google Scholar
• SIMPSON D, PLOSKER GL: Paclitaxel: as adjuvant or neoadjuvant therapy in early breast cancer. Drugs (2004) 64:1839-1847.
   PubMed Web of Science ®Google Scholar
• NAUMOV GN, TOWNSON JL, MacDONALD IC et al.: Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast. Cancer Res. Treat. (2003) 82:199-206.
   PubMed Web of Science ®Google Scholar
• GOTTESMAN MM: Mechanisms of cancer drug resistance. Ann. Rev. Med. (2002) 53:615-627.
   PubMed Web of Science ®Google Scholar
• GATTI L, ZUNINO F: Overview of tumor cell chemoresistance mechanisms. Methods Mol. Med. (2005) 111:127-148.
   PubMedGoogle Scholar
• GASPARINI G, LONGO R, TOI M, FERRARA N: Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol. (2005) 2:562-577.
   Google Scholar
• FERRARA N, KERBEL RS: Angiogenesis as a therapeutic target. Nature (2005) 438:967-974.
   PubMed Web of Science ®Google Scholar
• MARTIN E, GANTZ T, LEHRER R: Defensins and other endogenous peptide antibiotics of vertebrates. J. Leukoc. Biol. (1995) 58:128-136.
   Google Scholar
• ZASLOFF M: Antimicrobial peptides of multicellular organisms. Nature (2002) 415:389-395.
   PubMed Web of Science ®Google Scholar
• ZANETTI M: Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol. (2004) 75:39-48.
   Google Scholar
• McPHEE JB, HANCOCK RE: Function and therapeutic potential of host defence peptides. J. Pept. Sci. (2005) 11:677-687.
   Google Scholar
• MADER JS, SALSMAN J, CONRAD DM, HOSKIN DW: Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol. Cancer Ther. (2005) 4:612-624.
   Web of Science ®Google Scholar
• MOORE AJ, DEVINE DA, BIBBY MC: Preliminary experimental anticancer activity of cecropins. Pept. Res. (1994) 7:265-269.
   Google Scholar
• LICHTENSTEIN A, GANZ T, SELSTED ME, LEHRER RI: In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. Blood (1986) 68:1407-1410.
   PubMed Web of Science ®Google Scholar
• JACOB L, ZASLOFF M: Potential therapeutic applications of magainins and other antimicrobial agents of animal origin. Ciba. Found. Symp. (1994) 186:197-216.
   PubMedGoogle Scholar
• POWERS J-PS, HANCOCK REW: The relationship between peptide structure and antibacterial activity. Peptides (2003) 24:1681-1691.
   PubMed Web of Science ®Google Scholar
• LEUSCHNER C, HANSEL W: Membrane disrupting lytic peptides for cancer treatments. Curr. Pharm. Des. (2004) 10:2299-2310.
   PubMed Web of Science ®Google Scholar
• VAN HOFSTEN P, FAYE I, KOCKRUM K et al.: Sequence and specificity of cecropins A and B. Proc. Natl. Acad. Sci. USA (1985) 82:2240-2243.
   Google Scholar
• RISSO A, ZANETTI M, GENNARO R: Cytotoxicity and apoptosis mediated by two peptides of innate immunity. Cell. Immunol. (1998) 189:107-115.
   Web of Science ®Google Scholar
• FURLONG SJ, MADER JS, HOSKIN DW: Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen. Oncol. Rep. (2006) 15:1385-1390.
   Google Scholar
• KATSU T, NAKAO S, IWANAGA S: Mode of action of an antimicrobial peptide, tachyplesin I, on biomembranes. Biol. Pharm. Bull. (1993) 16:178-181.
   Google Scholar
• RAGHURAMAN H, CHATTOPADHYAY A: Cholesterol inhibits the lytic activity of melittin in erythrocytes. Chem. Phys. Lipids (2005) 134:183-189.
   PubMed Web of Science ®Google Scholar
• LI J, POST M, VOLK R et al.: PR39, a peptide regulator of angiogenesis. Nat. Med. (2000) 6:49-55.
   PubMed Web of Science ®Google Scholar
• KOCZULLA R, VON DEGENFELD G, KUPATT C et al.: An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. (2003) 111:1665-1672.
   Google Scholar
• YOO Y-C, WATANABE S, WATANABE R et al.: Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn J. Cancer Res. (1997) 88:184-190.
   Google Scholar
• CHAVAKIS T, CINES D, RHEE J-S et al.: Regulation of neovascularization by human neutrophil peptides (α-defensins): a link between inflammation and angiogenesis. FASEB J. (2004) 18:1306-1308.
   PubMed Web of Science ®Google Scholar
• YNAG D, BIRAGYN A, KWAK LW, OPPENHEIM JJ: Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. (2002) 23:291-296.
   Google Scholar
• HIEMSTRA PS, FERNIE-KING BA, McMICHAEL J et al.: Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapies. Curr. Pharm. Des. (2004) 10:2891-2905.
   PubMed Web of Science ®Google Scholar
• UTSUGI T, SCHROIT AJ, CONNOR J et al.: Elevated expression of phosphatidylserine in the outer leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. (1991) 51:3062-3066.
   PubMed Web of Science ®Google Scholar
• DOBRZYNSKA I, SZACHOWICZ-PETELSKA B, SULKOWSKI S, FIGASZEWSKI Z: Changes in electric charge and phospholipids composition in human colorectal cancer cells. Mol. Cell. Biochem. (2005) 276:113-119.
   Web of Science ®Google Scholar
• YOON WH, PARK HD, LIM K, HWANG BD: Effect of O-glycosylated mucin on invasion and metastasis of HM7 human colon cancer cells. Biochem. Biophys. Res. Commun. (1996) 222:694-699.
   PubMed Web of Science ®Google Scholar
• BURDICK MD, HARRIS A, REID CJ et al.: Oligosaccharides expressed on MUC1 by pancreatic and colon tumor cell lines. J. Biol. Chem. (1997) 272:24198-24202.
   PubMed Web of Science ®Google Scholar
• KOZLOWSKA K, NOWAK J, KWIATKOWSKI B, CICHOREK M: ESR study of plasmatic membrane of the transplantable melanoma cells in relation to their biological properties. Exp. Toxicol. Pathol. (1999) 51:89-92.
   Google Scholar
• SOK M, SENTJURC M, SCHARA M: Membrane fluidity characteristics of human lung cancer. Cancer Lett. (1999) 139:215-220.
   Web of Science ®Google Scholar
• DOMAGALA W, KOSS LG: Surface configuration of human tumor cells obtained by fine needle aspiration biopsy. Scan. Electron Microsc. (1980) 1:101-108.
   Google Scholar
• CHAUDHARY J, MUNSHI M: Scanning electron microscopic analysis of breast aspirates. Cytopathology (1995) 6:162-167.
   PubMed Web of Science ®Google Scholar
• BECHINGER B: The structure, dynamics and orientation of antimicrobial peptides in membranes by multidimensional solid-state NMR spectroscopy. Biochim. Biophys. Acta (1999) 1462:157-183.
   PubMed Web of Science ®Google Scholar
• YE J-S, ZHENG X-J, LEUNG KW et al.: Induction of transient ion channel-like pores in a cancer cell by antibiotic peptide. J. Biochem. (Tokyo) (2004) 136:255-259.
   Google Scholar
• SUI SF, WU H, GUO Y, CHEN KS: Conformational changes of melittin upon insertion into phospholipids monolayer and vesicles. J. Biochem. (1994) 116:482-487.
   Google Scholar
• LUDTKE SJ, HE K, WU Y, HUANG HW: Cooperative membrane insertion of magainin correlated with its cytolytic activity. Biochim. Biophys. Acta (1994) 1190:181-184.
   PubMed Web of Science ®Google Scholar
• HUANG HW: Action of antimicrobial peptides: two state model. Biochemistry (2000) 39:8347-8352.
   PubMed Web of Science ®Google Scholar
• DEKROON A, DOLIS D, MAYER A et al.: Phospholipid composition of highly purified mitochondrial outer membranes of rat liver and neurospora crassa. Is cardiolipin present in the mitochondrial outer membrane? Biochem. Biophys. Acta. (1997) 1325:108-116.
   PubMed Web of Science ®Google Scholar
• GRAY MW, BURGER G, LANG BF: Mitochondrial evolution. Science (1999) 283:1476-1481.
   PubMed Web of Science ®Google Scholar
• KIM R, EMI M, TANABE K: Role of mitochondria as the gardens of cell death. Cancer Chemother. Pharmacol. (2006) 57:545-553.
   Web of Science ®Google Scholar
• RISSO A, BRAIDOT E, SORDANO MC et al.: BMAP-28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition pore. Mol. Cell. Biol. (2002) 22:1926-1935.
   PubMed Web of Science ®Google Scholar
• ELIASSEN LT, BERGE G, LEKNESSUND A et al.: The antimicrobial peptide, Lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int. J. Cancer (2006) 119:493-500.
   PubMed Web of Science ®Google Scholar
• OKUMURA K, ITOH A, ISOGAI E et al.: C-terminal domain of human CAP18 antimicrobial peptide induces apoptosis in oral squamous cell carcinoma SAS-H1 cells. Cancer Lett. (2004) 212:185-194.
   Web of Science ®Google Scholar
• OHTAKE T, FUJIMOTO Y, IKUTA K et al.: Proline-rich antimicrobial peptide, PR-39 gene transduction altered invasive activity and actin structure in human hepatocellular carcinoma cells. Br. J. Cancer (1999) 81:393-403.
   PubMed Web of Science ®Google Scholar
• TANAKA K, FUJIMOTO Y, SUZUKI M et al.: PI3-kinase p85α is a target molecule of proline-rich antimicrobial peptide to suppress proliferation of ras-transformed cells. Jpn J. Cancer Res. (2001) 92:959-967.
   Google Scholar
• CHAN YR, GALLO RL: PR-39, a syndecan-inducing antimicrobial peptide, binds and affects p130(Cas). J. Biol. Chem. (1998) 273:28978-28985.
   PubMed Web of Science ®Google Scholar
• SANDGREN S, WITTRUP A, CHENG F et al.: The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. J. Biol. Chem. (2004) 279:17951-17956.
   PubMed Web of Science ®Google Scholar
• STEINER H, BENNICH H, BOMAN HG et al.: Sequence and specificity of 2 anti-bacterial proteins involved in insect immunity. Nature (1981) 292:246-248.
   PubMed Web of Science ®Google Scholar
• LEE JY, BOMAN A, SUN CX et al.: Antibacterial peptides from pig intestine: isolation of a mammalian cecropin. Proc. Natl. Acad. Sci. USA (1989) 86:19159-19162.
   Google Scholar
• CHEN HM, WANG W, SMITH D, CHAN SC: Effects of the anti-bacterial peptide cecropin B and its analogs, cecropins B-1 and B-2, on liposomes, bacteria and cancer cells. Biochim. Biophys. Acta. (1997) 1336:171-179.
   PubMed Web of Science ®Google Scholar
• SRISAILAM S, ARUNKUMAR AI, WANG W et al.: Conformational study of a custom antibacterial peptide cecropin B1: implications of the lytic activity. Biochim. Biophys. Acta (2000) 1479:275-285.
   PubMed Web of Science ®Google Scholar
• HUI L, LEUNG K, CHEN HM: The combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cells. Anticancer Res. (2002) 22:2811-2816.
   PubMed Web of Science ®Google Scholar
• HUNG SC, WANG W, CHAN SI, CHEN HM: Membrane lysis by the antibacterial peptides cecropins B1 and B3: a spin-label electron spin resonance study on phospholipid bilayers. Biophys. J. (1999) 77:3120-3133.
   PubMed Web of Science ®Google Scholar
• ZASLOFF M: Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc. Natl. Acad. Sci. USA (1987) 84:5449-5453.
   Google Scholar
• OHSAKI Y, GAZDAR AF, CHEN H-C, JOHNSON BE: Antitumor activity of magainin analogues against human lung cancer cell lines. Cancer Res. (1992) 52:3534-3538.
   PubMed Web of Science ®Google Scholar
• TAKESHIMA K, CHIKUSHI A, LEE K-K et al.: Translocation of analogues of the antimicrobial peptides magainin and buforin across human cell membranes. J. Biol. Chem. (2003) 278:1310-1315.
   PubMed Web of Science ®Google Scholar
• HAUKLAND HH, ULVATNE H, SANDVIK K, VORLAND LH: The antimicrobial peptides lactoferricin B and magainin 2 cross over the bacterial cytoplasmic membrane and reside in the cytoplasm. FEBS Lett. (2001) 508:389-393.
   PubMed Web of Science ®Google Scholar
• WESTERHOFF HV, HENDLER RW, ZASLOFF M, JURETIC D: Interactions between new class of eukaryotic antimicrobial agents and isolated rat mitochondria. Biochem. Biophys. Acta (1989) 975:361-369.
   PubMed Web of Science ®Google Scholar
• BAKER MA, MALOY WL, ZASLOFF M, JACOB LS: Anticancer efficacy of magainin 2 and analogue peptides. Cancer Res. (1993) 53:3052-3057.
   PubMed Web of Science ®Google Scholar
• GAULDIE J, HANSON JM, SHIPOLINI RA, VERNON CA: The structures of some peptides from bee venom. Eur. J. Biochem. (1978) 83:405-410.
   Web of Science ®Google Scholar
• HRISTOVA K, DEMPSEY CE, WHITE SH: Structure, location, and lipid perturbations of melittin at the membrane interface. Biophys. J. (2001) 80:801-811.
   PubMed Web of Science ®Google Scholar
• SHARMA SV: Melittin-induced hyperactivation of phospholipase A2 activity and calcium influx in ras-transformed cells. Oncogene (1993) 8:939-947.
   PubMed Web of Science ®Google Scholar
• SHARMA SV: Melittin resistance: a counterselection for ras transformation. Oncogene (1992) 7:193-201.
   PubMed Web of Science ®Google Scholar
• HOLLE L, SONG W, HOLLE F et al.: A matrix metalloproteinase 2 cleavable melittin/avidin conjugate specifically targets tumor cells in vitro and in vivo. Int. J. Oncol. (2003) 22:93-98.
   Web of Science ®Google Scholar
• VIHINEN P, KAHARI VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer (2002) 10:155-167.
   Web of Science ®Google Scholar
• RISSO A: Leukocyte antimicrobial peptides: multifunctional effector molecules of innate immunity. J. Leukoc. Biol. (2000) 68:785-792.
   Google Scholar
• HECHT G: Innate mechanisms of epithelial host defense: spotlight on intestine. Am. J. Physiol. (1999) 277:351-358.
   Google Scholar
• LEHRER RI, GANZ T: Defensins of vertebrate animals. Curr. Opin. Immunol. (2002) 14:96-102.
   PubMed Web of Science ®Google Scholar
• KAGAN BL, SELSTED ME, GANZ T, LEHRER RI: Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes. Proc. Natl. Acad. Sci. USA (1990) 87:210-214.
   Google Scholar
• NISHIMURA M, ABIKO Y, KURASHIGE Y et al.: Effect of defensin peptides on eukaryotic cells: primary epithelial cells, fibroblasts and squamous cell carcinoma cell lines. J. Dermatol. Sci. (2004) 36:87-95.
   Google Scholar
• TOMITA M, BELLAMY W, TAKASE M et al.: Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. J. Dairy Sci. (1992) 74:4137-4142.
   Web of Science ®Google Scholar
• DIPAOLA C, MANDEL ID: Lactoferrin concentration in human parotid saliva as measured by an enzyme-linked immunosorbent assay (ELISA). J. Dent. Res. (1980) 59:1463-1465.
   PubMed Web of Science ®Google Scholar
• MASSON PL, HEREMANS JF: Lactoferrin in milk from different species. Comp. Biochem. Physiol. B (1971) 39:119-129.
   Google Scholar
• MASSON PL, HEREMANS JF, SCHONNE E: Lactoferrin, an iron-binding protein in neutrophilic leukocytes. J. Exp. Med. (1969) 130:643-658.
   PubMed Web of Science ®Google Scholar
• ARNOLD RR, COLE MF, McGHEE JR: A bactericidal effect for human lactoferrin. Science (1997) 197:263-265.
   Google Scholar
• VORLAND LH, ULVATNE H, ANDERSEN J et al.: Lactoferricin of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scand. J. Infect. Dis. (1998) 30:513-517.
   PubMed Web of Science ®Google Scholar
• HWANG PM, ZHOU N, SHAN X et al.: Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry (1998) 37:4288-4298.
   PubMed Web of Science ®Google Scholar
• ELIASSEN LT, BERGE G, SVEINBJØRNSSON B et al.: Evidence for a direct antitumour mechanism of action of bovine lactoferricin. Anticancer Res. (2002) 22:2703-2710.
   PubMed Web of Science ®Google Scholar
• ROY MK, KUWABARA Y, WATANABE Y, TAMAI Y: Peptides form the N-terminal end of bovine lactoferrin induce apoptosis in human leukemic (HL-60) cells. J. Dairy Sci. (2002) 85:2065-2074.
   Web of Science ®Google Scholar
• YOO Y-C, WATANABE R, KOIKE Y et al.: Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: involvement of reactive oxygen species. Biochem. Biophys. Res. Commun. (1997) 237:624-628.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, FURUNAKA H, MIYATA T et al.: Tachyplesin, a class of anti-microbial peptide from the hemocytes of the horseshoe crab (Tachypleus tridentatus). Isolation and chemical structure. J. Biol. Chem. (1988) 263:16709-16713.
   PubMed Web of Science ®Google Scholar
• RAO AG: Conformation and antimicrobial activity of linear derivatives of tachyplesin lacking disulfide bonds. Arch. Biochem. Biophys. (1999) 361:127-134.
   Google Scholar
• OUYANG GL, LI QF, PENG XX et al.: Effects of tachyplesin on proliferation and differentiation of human hepatocellular carcinoma SMMC-771 cells. World J. Gastroenterol. (2002) 8:1053-1058.
   Web of Science ®Google Scholar
• CHEN Y, XU X, HONG S et al.: RGD-tachyplesin inhibits tumor growth. Cancer Res. (2001) 61:2434-2438.
   PubMed Web of Science ®Google Scholar
• CHEN J, XU X-M, UNDERHILL CB et al.: Tachyplesin activates the classic complement pathway to kill tumor cells. Cancer Res. (2005) 65:4614-4622.
   PubMed Web of Science ®Google Scholar
• SHIN SY, LEE MK, KIM KL, HAHM K-S: Structure–antitumor and hemolytic activity relationships of synthetic peptides derived from cecropin A-magainin 2 and cecropin A-melittin hybrid peptides. J. Pept. Res. (1997) 50:279-285.
   Google Scholar
• SHIN SY, LEE S-H, YANG S-T: Antibacterial, antitumor and hemolytic activities of α-helical antibiotic peptide, P18 and its analogues. J. Pept. Res. (2001) 58:504-514.
   Google Scholar
• ROBERTSON CN, ROBERSON KM, PINERO A et al.: Peptidyl membrane-interactive molecules are cytotoxic to prostate cancer cells in vitro. World J. Urol. (1998) 16:405-409.
   Web of Science ®Google Scholar
• ARLOTTI JA, CIMINO TS, NGUYEN T-S et al.: Efficacy of a synthetic lytic peptide in the treatment of prostate cancer. Urol. Oncol. (2001) 6:97-102.
   PubMed Web of Science ®Google Scholar
• SMITH CA, HINMAN CL: A cyclic peptide, L1AD3, induces early signs of apoptosis in human leukemic T-cell lines. J. Biochem. Mol. Toxicol. (2004) 4:204-220.
   Google Scholar
• ELLERBY HM, ARAP W, ELLERBY LM et al.: Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. (1999) 5:1032-1038.
   PubMed Web of Science ®Google Scholar
• HANSEL W, LEUSCHNER C, GAWRONSKA B, ENRIGHT F: Targeted destruction of prostate cancer cells and xenografts by lytic peptide-βLH conjugates. Reprod. Biol. (2001) 1:20-32.
   Google Scholar
• GAWRONSKA B, LEUSCHNER C, ENRIGHT FM, HANSEL W: Effects of a lytic peptide conjugated to β hCG on ovarian cancer: studies in vitro and in vivo. Gynecol. Oncol. (2002) 85:45-52.
   PubMed Web of Science ®Google Scholar
• WARREN P, LI L, SONG W et al.: In vitro targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two γ-linked glutamate residues at the COOH terminus. Cancer Res. (2001) 61:6783-6787.
   PubMed Web of Science ®Google Scholar
• GHOSH A, WANG X, KLEIN E, HESTON WD: Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res. (2005) 65:727-31.
   PubMed Web of Science ®Google Scholar
• RUSSELL PJ, HEWISH D, CARTER T et al.: Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies. Cancer Immunol. Immunother. (2004) 53:411-421.
   Web of Science ®Google Scholar
• KUMAR CS, LEUSCHNER C, DOOMES EE et al.: Efficacy of lytic peptide-bound magnetite nanoparticles in destroying breast cancer cells. J. Nanosci. Nanotechnol. (2004) 4:245-249.
   Google Scholar
• SWENSON S, COSTA F, MINEA R et al.: Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. Mol. Cancer Ther. (2004) 3:499-511.
   Web of Science ®Google Scholar
• YAMADA Y, SHINOHARA Y, KAKUDO T et al.: Mitochondrial delivery of mastoparan with transferring liposomes equipped with a pH-sensitive fusogenic peptide for selective cancer therapy. Int. J. Pharm. (2005) 303:1-7.
   Web of Science ®Google Scholar
• WOODLE MC: Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation. Chem. Phys. Lipids (1993) 64:249-262.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. (2001) 46:149-168.
   Google Scholar
• SENGUPTA S, EAVARONE D, CAPILA I et al.: Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature (2005) 436:568-572.
   PubMed Web of Science ®Google Scholar
• PFEIFFER DR, GUDZ TI, NOVGORODOV SA, ERDAHL WL: The peptide mastoparan is a potent facilitator of the mitochondrial permeability transition. J. Biol. Chem. (1995) 270:4923-2932.
   PubMed Web of Science ®Google Scholar
• KWOK JC, RICHARDSON DR: The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit. Rev. Oncol. Hematol. (2002) 42:65-78.
   Google Scholar
• TOP D, DE ANTUENO R, SALSMAN J et al.: Liposome reconstitution of a minimal protein-mediated membrane fusion machine. EMBO J. (2005) 24:2980-2988.
   PubMed Web of Science ®Google Scholar
• LING CQ, LI B, ZHANG DZ et al.: Inhibitory effect of recombinant adenovirus carrying melittin gene on heptocellular carcinoma. Ann. Oncol. (2005) 16:109-115.
   Google Scholar
• WINDER D, GÜNZBURG WH, ERFLE V, SALMONS B: Expression of antimicrobial peptides has an antitumour effect in human cells. Biochem. Biophys. Res. Commun. (1998) 242:608-612.
   PubMed Web of Science ®Google Scholar
• THOMAS CE, EHRHARDT A, KAY MA: Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. (2003) 4:346-358.
   PubMed Web of Science ®Google Scholar
• PETTUS BJ, CHALFANT CE, HANNUN YA: Ceramide in apoptosis: an overview and current perspectives. Biochim. Biophys. Acta (2002) 1585:114-125.
   PubMed Web of Science ®Google Scholar
• RAN S, DOWNES A, THORPE PE: Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. (2002) 62:6132-6140.
   PubMed Web of Science ®Google Scholar
• PANYUTICH AV, VOITENOK NN, LEHRER RI, GANZ T: An enzyme immunoassay for human defensins. J. Immunol. Methods (1991) 141:149-155.
   Google Scholar
• MULLER WD, FAHLBUSCH B, JUNG K et al.: Characterization of murine monoclonal antibodies to phospholipase A2 and mellitin from bee venom. Int. Arch. Allergy Immunol. (1993) 101:153-158.
   PubMed Web of Science ®Google Scholar
• SHIMAZAKI K, NAM MS, HARAKAWA S et al.: Monoclonal antibody against bovine lactoferricin and its epitopic site. J. Vet. Med. Sci. (1996) 58:1227-1229.
   Google Scholar
• SORENSEN O, COWLAND JB, ASKAA J, BORREGAARD N: An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. J. Immunol. Methods (1997) 206:53-59.
   Google Scholar
• PAPO N, SHAI Y: New lytic peptides based on the D,L-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry (2003) 42:9346-9354.
   PubMed Web of Science ®Google Scholar
• PAPO N, SHAHAR M, EISENBACH L, SHAI Y: A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice. J. Biol. Chem. (2003) 278:21018-21023.
   PubMed Web of Science ®Google Scholar
• PAPO N, BRAUNSTEIN A, ESHHAR Z, SHAI Y: Suppression of human prostate growth in mice by a cytolytic D-,L-amino acid peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res. (2004) 64:5779-5786.
   PubMed Web of Science ®Google Scholar
• SKERLAVAJ B, GENNARO R, BAGELLA L et al.: Biological characterization of two novel cathelicidin-derived peptides and indentification of structural requirements for their antimicrobial and cell lytic activity. J. Biol. Chem. (1996) 271:28375-28381.
   PubMed Web of Science ®Google Scholar
• BOMAN HG, FAYE I, HOFSTEN VP et al.: On the primary structures of lysozyme, cecropins and attacins from Hyalophora cecropia. Dev. Comp. Immunol. (1985) 9:551-558.
   PubMed Web of Science ®Google Scholar
• JAYNES JM, JULIAN GR, JEFFERS GW et al.: In vitro cytocidal effect of lytic peptides on several transformed mammalian cell lines. Pept. Res. (1989) 2:157-160.
   Google Scholar
• SELSTED ME, HARWIG SS, GANZ T et al.: Primary structures of three human defensins. J. Clin. Invest. (1985) 76:1436-1439.
   Google Scholar
• WILDE CG, GRIFFITH JE, MARRA MN et al.: Purification and characterization of human neutrophil peptide 4, a novel member of the defensin family. J. Biol. Chem. (1989) 264:11200-11203.
   PubMed Web of Science ®Google Scholar
• BENSCH KW, RAIDA M, MAGERT HJ et al.: hBD-1: a novel β-defensin from human plasma. FEBS Lett. (1995) 368:331-335.
   Google Scholar
• BALS R, WANG X, WU Z: Human β-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J. Clin. Invest. (1998) 102:874-880.
   Google Scholar
• BELLAMY W, TAKASE M, WAKABAYASHI H et al.: Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J. Appl. Bacteriol. (1992) 73:472-479.
   Google Scholar
• ZASLOFF M, MARTIN B, CHEN H-C: Antimicrobial activity of synthetic magainin peptides and several analogues. Proc. Natl. Acad. Sci. USA (1988) 85:910-913.
   Google Scholar
• KREIL G: Biosynthesis of melittin, a toxic peptide from bee venom. Amino-acid sequence of the precursor. Eur. J. Biochem. (1973) 33:558-566.
   Google Scholar